1 Top Growth Stock to Buy and Hold for 10 Years
A lot will change in the next 10 years, but our need for innovative medicines is unlikely to be one of them. That's one thing that makes some biotech companies exciting long-term investment opportunities, at least highly innovative ones that look well-positioned to deliver solid clinical and regulatory progress over long periods.
Let's consider one company that might have what it takes: Sarepta Therapeutics (NASDAQ: SRPT). The biotech has performed well so far this year, and it could maintain that momentum for a while. Let's find out why.
Sarepta Therapeutics' strong performance on the stock market this year reflects the fact that investors expect it to earn a crucial approval from the U.S. Food and Drug Administration (FDA). But first, some background information.
Source Fool.com
Sarepta Therapeutics Stock
The community is currently still undecided about Sarepta Therapeutics with 1 Buy predictions and 0 Sell predictions.
On the other hand, the target price of 130 € is below the current price of 133.5 € for Sarepta Therapeutics, so the potential is actually -2.62%.
